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Abstract
Background: Based on the results of clinical trials, the prognosis for patients with severe
heart failure (HF) has improved over the last 20 years. However, clinical trials do not reflect ‘real
life’ due to patient selection. Thus, the aim of the POLKARD-HF registry was the analysis of
survival of patients with refractory HF referred for orthotopic heart transplantation (OHT).
Methods: Between 1 November 2003 and 31 October 2007, 983 patients with severe HF,
referred for OHT in Poland, were included into the registry. All patients underwent routine
clinical and hemodynamic evaluation, with NT-proBNP and hsCRP assessment. Death or an
emergency OHT were assumed as the endpoints. The average observation period was 601 days.
Kaplan-Meier curves with log-rank and univariate together with multifactor Cox regression
model the stepwise variable selection method were used to determine the predictive value of
analyzed variables.
Results: Among the 983 patients, the probability of surviving for one year was approximately
80%, for two years 70%, and for three years 67%. Etiology of the HF did not significantly
influence the prognosis. The patients in NYHA class IV had a three-fold higher risk of death or
emergency OHT. The univariate/multifactor Cox regression analysis revealed that NYHA
IV class (HR 2.578, p < 0.0001), HFSS score (HR 2.572, p < 0.0001) and NT-proBNP plasma
level (HR 1.600, p = 0.0200), proved to influence survival without death or emergency OHT.
Conclusions: Despite optimal treatment, the prognosis for patients with refractory HF is still
not good. NYHA class IV, NT-proBNP and HFSS score can help define the highest risk group.
The results are consistent with the prognosis of patients enrolled into the randomized trials.
(Cardiol J 2012; 19, 1: 36–44)
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Introduction
Based on results from randomized trials, one
should expect a significant improvement of prog-
nosis in patients with heart failure (HF), including
the group of patients with severe HF (NYHA class IV)
[2–5]. Moreover, an evaluation of the prognosis in
patients has been performed according to the class
of HF and type of applied pharmacological therapy
[6]. Thus the purpose of the POLKARD-HF study
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was to register and evaluate patients, initially quali-
fied for heart transplantation due to refractory HF,
with regard to factors influencing prognosis in this
group of patients [7].
Methods
An informed consent was obtained from each
patient participating in the study according to the
protocol approved by the Local Ethics Committee.
The investigation conformed with the principles
outlined in the Declaration of Helsinki. Between
1 November 2003 and 31 October 2007, 983 patients
with severe HF, initially considered for orthotopic
heart transplantation (OHT), were included into the
registry. Finally, after treatment correction and
detailed evaluation, 658 patients were qualified for
OHT, 306 patients for further observations, and
19 patients were not qualified for OHT due to con-
traindications (in accordance with recommendations
of The International Society for Heart and Lung
Transplantation and the European Society of Car-
diology). The average period of observation was
601 days (range 1–1,462 days). Tests for qualifica-
tion for OHT included standard clinical evaluation,
biochemical evaluation (sodium, NT-proBNP,
hsCRP serum concentration), six-minute walking
test (6-MWT), maximal oxygen uptake (VO2max),
echocardiographic, electrocardiographic and hemo-
dynamic assessment. Also, Heart Failure Survival
Score (HFSS) according to Aaronson was calculat-
ed [8]. A value of the score between 8.1–10.5 was
considered as low risk;  7.2–8.09 was considered as
moderate risk; and 5.5–7.19 was considered as high
risk.
NT-proBNP levels (pg/mL) were determined
using electroluminescence immunoassays (Roche
Diagnostics, the limit of detection was 50 pg/mL).
Concentration of hsCRP was conducted with the
turbidimetric method amplified by latex particles.
This method is standardized in accordance with
IFCC/BCR/CAP in compliance with CRM 470 stan-
dard for 14 serum proteins. The limit of detection
was 0.71 mg/L.
Statistical analysis
Death or an emergency heart transplantation
(UNOS status 1) were assumed as the endpoints in
the follow-up. The following descriptive statistical
methods were used for presenting results: means,
standard deviations, medians and quartiles in distri-
bution. Comparison of analyzed continuous parame-
ters was conducted using the analysis of variance
(Duncan test) with met criteria for normal distribu-
tion (verified with Shapiro-Wilk test), but in case of
departure from normality, non-parametrical Mann-
-Whitney-Wilcoxon test or Kruskal-Wallis test was
used. For evaluation of the survival rate in the ter-
cile groups and NYHA groups, Kaplan-Meier curves
were used together with the log-rank test for verifi-
cation of a hypothesis on homogeneity of the survival
rate curves. Prediction value of the analyzed varia-
bles in terms of occurrence of the endpoint was
analyzed using the Cox regression method with sin-
gle-variable. Multifactor Cox regression model was
built with the stepwise variable selection method,
introducing crucial predictors into the model, which
were defined in the single-variable regression. Sig-
nificance of type I error was established at the level
of 0.05. Statistical analyses were conducted using the
statistical package (SAS version 9.1).
Results
Male patients constituted the majority (87.8%)
of the 983 patients enrolled into the registry, with
a mean age just below 50 years. Body mass index
(BMI) did not significantly differ from normal. The
left ventricular ejection fraction (LVEF) was se-
verely compromised, together with end systolic/
/diastolic dilatation, elevated NT-proBNP and
hsCRP (Table 1). The patients presented modera-
te pulmonary hypertension. An Aaronson score
equal to 7.7 indicated a moderate risk of death.
HF was caused by dilated cardiomyopathy
(486 patients; 49.4%), and ischemic cardiomyopa-
thy (425 patients; 43.2%) whereas hypertrophic car-
diomyopathy, acquired/congenital heart defects and
arrhythmias constituted only 5.1% of cases. There
was no information about etiology in the remaining
2.3% of patients. All patients were treated with
optimal tolerated doses of angiotensin converting
enzyme inhibitors, beta-blockers and diuretics as
judged by treating cardiologists in HF or transplan-
tology departments.
Among the 983 patients initially considered,
the probability of not reaching the end-point dur-
ing the first year of follow-up was approximately
80%, at two years about 70%, and at three years
around 67% (Fig. 1).
Out of 658 patients finally qualified for OHT,
164 subjects (24.9%) reached the end event (105 su-
bjects died, and 59 underwent emergency OHT).
Prognosis with regard to heart failure etiology
Patients with ischemic HF were older than
patients with dilated cardiomyopathy. The groups
differed not only in terms of LV size and function,
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but there were also significant differences in NT-
-proBNP concentration, VO2max and HFSS (Table 2).
Despite the aforementioned differences, the proba-
bility of the survival rate in both compared groups
(Kaplan-Meier survival curves) was similar (Fig. 2).
Prognosis with regard to
functional NYHA classification
Out of the 983 patients initially considered for
OHT, 19.8% presented NYHA class II, 55% NYHA
class III, and 24.5% were in NYHA class IV (Table 3).
Patients with NYHA classes III and IV differed sig-
nificantly in terms of the majority of comparable
parameters, except for dimensions of the LV, pa-
rameters evaluating pulmonary circulation, and
maximum oxygen consumption. NYHA class IV pa-
tients differed significantly with regard to LVEF,
heart rate, systemic arterial pressure, pulmonary
capillary wedge pressure, and cardiac index. The
level of NT-proBNP and hsCRP was two-fold higher
in NYHA class IV. Low HFSS indicated a high risk
of death. Also BMI and sodium concentration were
significantly lower in the most severe form of HF.
A comparison between patients with NYHA
classes II and III revealed that differences were
related to structure and function of the LV and also
to heart rate and value of the systemic systolic ar-
terial pressure. Patients in NYHA class II present-
ed lower capillary pulmonary pressure, whereas
cardiac index was higher compared to subjects with
NYHA class III. Similarly, pulmonary artery systolic
pressure, as well as pulmonary gradient, and pul-
monary vascular resistance, were significantly
Table 1. Baseline characteristics of patients from
the POLKARD-HF registry.
Parameter N Mean ± SD;
Median [min–max]
Age [years] 983 49.38 ± 11.245
Weight [kg] 982 77.9 ± 15.42
Height [cm] 980 172.8 ± 9.71
BMI [kg/m2] 979 25.982 ± 4.5004
LVEF [%] 978 21.6 ± 8.13
LVEDD [mm] 953 71.93 ± 10.472
LVESD [mm] 905 60.30 ± 13.217
HR [1/min] 962 78.3 ± 15.80
SBP [mm Hg] 975 102.6 ± 14.97
DBP [mm Hg] 975 67.0 ± 11.12
PASP [mm Hg] 629 44.9 ± 17.41
PCWP [mm Hg] 695 20.8 ± 9.41
CI [L/min] 530 1.95 ± 0.854
PVR [Wood Units] 643 3.13 ± 2.392
Gradient [mm Hg] 654 10.61 ± 6.677
hs-CRP [mg/L] 679 3.00
[0.03–347.00]
NT-proBNP [pg/mL] 694 2,294.5
[28.0–46,128.0]
VO2max [mL/kg/min] 687 13.05 ± 4.345
HFSS 952 7.7 ± 0.98
Na [mEq/L] 973 136.4 ± 4.41
BMI — body mass index; LVEF — left ventricular ejection fraction;
LVEDD — left ventricular end-diastolic diameter; LVESD — left ventri-
cular end-systolic diameter; HR — heart rate; SBP — systolic arterial
blood pressure; DBP — diastolic arterial blood pressure; PASP —
pulmonary artery systolic pressure; PCWP — pulmonary mean wedge
pressure; CI — cardiac index; PVR — pulmonary vascular resistance;
Gradient — transpulmonary gradient; hs-CRP — hs-C-reactive protein;
NT-proBNP — N-terminal natriuretic brain pro-peptide; VO2max —
maximal oxygen uptake; HFSS — Heart Failure Survival Score;
Na — Na serum concentration
Figure 1. Probability of survival without emergency heart transplantation. Reprinted from: [1], with permission from
Elsevier.
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Table 2. Comparison of baseline parameters of POLKARD-HF patients stratified by ischemic vs
non-ischemic cardiomyopathy (CM).
Parameter Ischemic CM         Dilated CM P
N Mean ± SD; N Mean ± SD;
Median [min–max] Median [min–max]
Age [years] 425 54.57 ± 6.013 486 45.80 ± 12.132 < 0.0001
Weight [kg] 424 78.5 ± 13.83 486 78.5 ± 16.02 0.7699
Height [cm] 423 172.2 ± 11.01 485 173.8 ± 7.38 0.0059
BMI [kg/m2] 422 26.355 ± 3.8408 485 25.947 ± 4.8994 0.0567
NYHA 421 3.1 ± 0.63 484 3.0 ± 0.70 0.2405
LVEF [%] 424 21.7 ± 7.01 485 20.7 ± 7.23 0.0114
LVEDD [mm] 409 71.20 ± 8.733 476 73.75 ± 10.552 < 0.0001
LVESD [mm] 386 59.41 ± 11.598 453 62.29 ± 13.389 < 0.0001
HR [1/min] 419 76.2 ± 13.15 472 80.3 ± 17.59 0.0022
SBP [mm Hg] 424 103.1 ± 14.79 480 102.6 ± 15.20 0.7361
DBP [mm Hg] 424 67.5 ± 11.33 480 66.9 ± 10.92 0.5074
PASP [mm Hg] 288 45.7 ± 18.48 297 44.8 ± 15.99 0.5635
PCWP [mm Hg] 315 20.9 ± 9.88 335 21.0 ± 9.00 0.7334
CI [L/min] 241 1.95 ± 0.619 257 1.95 ± 1.044 0.2153
PVR [Wood Units] 300 3.27 ± 2.555 301 3.10 ± 2.234 0.8758
Gradient [mm Hg] 300 10.86 ± 6.360 313 10.64 ± 7.065 0.4930
hs-CRP [mg/L] 302 3.00 [0.03–134.40] 337 3.20 [0.03–347.00] 0.9704
NT-proBNP [pg/mL] 298 2,094.0 [87.5–26,742.0] 349 2,452.0 [28.0–45,515.0] 0.0093
VO2max [mL/kg/min] 310 12.32 ± 3.791 338 13.82 ± 4.770 < 0.0001
HFSS 417 7.4 ± 0.83 467 8.0 ± 0.96 < 0.0001
Na [mEq/L] 423 136.4 ± 4.33 480 136.3 ± 4.50 0.7277
Abbreviations as in Table 1.
Figure 2. Probability of survival without emergency heart transplantation — patients stratified by ischemic vs
non-ischemic cardiomyopathy (CM). Reprinted from: [1], with permission from Elsevier.
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Table 3. Comparison of baseline parameters of POLKARD-HF patients stratified by NYHA class at admission.
Parameter NYHA II NYHA III NYHA IV NYHA II vs III NYHA II vs IV NYHA III vs IV
N Mean ± SD; N Mean ± SD; N Mean ± SD;  
P  P   P
Median [min–max]  Median [min–max]  Median [min–max]
Age [years] 195 48.17 ± 10.746 541 50.84 ± 10.068 241 47.02 ± 13.465 0.0003 0.6798 0.0034
Weight [kg] 195 79.0 ± 15.24 541 78.6 ± 15.42 240 75.3 ± 15.38 0.6587 0.0305 0.0017
Height [cm] 195 172.9 ± 7.22 541 172.6 ± 11.30 238 173.1 ±  7.33 0.7290 0.9867 0.7247
BMI [kg/m2] 195 26.382 ± 4.7020 540 26.254 ± 4.4201 238 24.999 ± 4.4267 0.8400 0.0057 0.0002
LVEF [%] 194 25.8 ± 9.56 540 21.6 ± 7.71 238 18.4 ± 6.10 < 0.0001 < 0.0001 < 0.0001
LVEDD [mm] 189 71.07 ± 9.319 526 72.19 ± 11.068 232 72.01 ± 10.052 0.1306 0.5893 0.3240
LVESD [mm] 181 58.62 ± 11.635 498 60.59 ± 14.040 220 61.05 ± 12.496 0.0078 0.0467 0.6348
HR [1/min] 194 74.2 ± 16.10 528 78.0 ± 14.72 234 82.5 ± 17.08 0.0008 < 0.0001 0.0013
SBP [mm Hg] 194 106.3 ± 15.28 537 103.5 ± 14.80 238 97.3 ± 13.90 0.0224 < 0.0001 < 0.0001
DBP [mm Hg] 194 68.9 ± 11.59 537 67.3 ± 10.98 238 64.4 ± 10.66 0.1041 0.0001 0.0027
PASP [mm Hg] 92 39.2 ± 16.24 371 44.9 ± 16.83 160 47.8 ± 18.25 0.0030 0.0003 0.1138
PCWP [mm Hg] 95 18.4 ± 10.03 404 20.5 ± 9.10 190 22.9 ± 9.44 0.0171 < 0.0001 0.0077
CI [L/min] 72 2.08 ± 0.678 312 1.96 ± 0.639 141 1.89 ± 1.265 0.0065 0.0001 0.0110
PVR [Wood Units] 87 2.45 ± 1.661 376 3.09 ± 2.268 174 3.48 ±  2.739 0.0061 0.0006 0.1352
Gradient [mm Hg] 93 8.71 ± 4.624 375 10.87 ± 6.780 180 10.88 ± 7.022 0.0084 0.0479 0.6775
hs-CRP [mg/L] 170 2.19 [0.03–134.40] 381 2.80 [0.03–196.80] 124 6.84 [0.14–347.00] 0.0720 < 0.0001 < 0.0001
NT-proBNP [pg/mL] 173 1,396.0 [28.0–15,616.0] 382 2,297.5 [122.6–46,128.0] 137 4,255.0 [87.5–37,605.0] < 0.0001 < 0.0001 < 0.0001
VO2max [mL/kg/min] 159 16.90 ± 4.505 416 11.95 ± 3.630 107 11.53 ± 3.265 < 0.0001 < 0.0001 0.1675
HFSS 193 8.4 ± 0.98 521 7.7 ± 0.84 232 7.2 ± 0.90 < 0.0001 < 0.0001 < 0.0001
Na [mEq/L] 194 137.7 ± 3.43 532 136.6 ±  4.13 241 134.8 ± 5.21 0.0002 < 0.0001 < 0.0001
Abbreviations as in Table 1.
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lower in NYHA class II. The following parameters:
LVEF, heart rate, systemic systolic arterial pres-
sure, pulmonary capillary pressure, cardiac index,
NT-proBNP, HFSS, and sodium concentration dif-
ferentiated all NYHA classes (II vs III, II vs IV, and
III vs IV) (Fig. 3). However, the prognosis in pa-
tients with NYHA class II and III was similar,
whereas NYHA class IV had a worse prognosis. The
probability of six-month survival in most sick pa-
tients was 60%, one-year survival rate was approxi-
mately 50%, and three-year survival rate was ap-
proximately 40%.
Risk factors for death or emergency OHT
The following values of analyzed parameters in
Kaplan-Meier survival analysis differentiated the gro-
ups: pulmonary artery systolic pressure ≥ 50 mm Hg,
pulmonary capillary wedge pressure ≥ 25 mm Hg,
LVEF £ 17%, functional NYHA class IV, systemic
systolic arterial pressure £ 90 mm Hg, hsCRP
≥ 6.5 mg/L, NT-proBNP level ≥ 4302 pg/mL, se-
rum Na concentration £ 135 mEq/L, BMI £ 23.8,
and HFSS £ 7.19. However, only persisting symp-
toms compatible with NYHA class IV despite ade-
quate treatment are clearly an indicator of bad prog-
nosis (Fig. 3).
Univariate Cox regression analysis revealed
a few factors influencing survival without emergen-
cy OHT (Table 4). However, among all factors in-
fluencing survival from univariate analysis, in the
Figure 3. Probability of survival without end-points — patients stratified by NYHA class at admission.
multifactor Cox regression model, only NYHA IV
class (HR 2.578, p < 0.0001), HFSS score (HR
2.572, p < 0.0001) and NT-proBNP plasma level
(HR 1.600, p = 0.0200), proved to influence sur-
vival without death or emergency OHT (Table 5).
Discussion
Significant progress in the treatment of HF
has occurred within the last 20 years. This in-
cludes pharmacological treatment, cardiac sur-
gery and electrotherapy [9–12]. In a work pub-
lished in 1991, and related to the era of HF treat-
ment with digitalis and diuretics, one-year
survival rate in patients with NYHA class II was
established at 98%, and three-year survival rate
at 85%; the survival rate in patients with func-
tional NYHA class III was 80% and 55%, respec-
tively. Moreover, the one-year mortality rate in
patients with severe HF exceeded 50% at that
time [4]. In 2001, based on meta-analysis of ran-
domized drug trials in patients with HF, Cleland
et al. [6] established a two-year mortality rate in
patients with moderate HF at approximately 34%,
and the one-year mortality rate in patients with
severe HF was 52% (data regarding control
groups receiving a placebo). Unusual progress in
the treatment of systolic HF included the intro-
duction of angiotensin convertase inhibitors and
beta-adrenergic receptor blockers.
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In the Consensus I study in patients with sys-
tolic HF with NYHA class IV, the administration of
enalapril reduced the six-month mortality rate by
40% (44% in the control group vs 26% in the thera-
peutic group) and one-year mortality rate by 31%.
Reduction in the mortality rate by 16% (SOLVD)
to 33% (V-HeFT II) was obtained in other studies
evaluating the effects of the administration of an-
giotensin convertase inhibitors in patients with less
advanced HF. The only study evaluating the effects
of the drugs blocking beta-adrenergic receptors in
patients with severe HF (NYHA class IV) was the
COPERNICUS trial [13, 14]. One-year mortality
rate in the group of patients receiving a placebo was
18.5%, significantly lower than it was in the studies
mentioned above; a 35% reduction in risk of death
was obtained in patients receiving a beta-blocker. In
collective analysis of the CIBIS II, MERIT HF, and
COPERNICUS studies, the following results (pla-
cebo group vs therapeutic group) were obtained:
NYHA class II — 7.2% vs 5.4%; NYHA class III —
12.3% vs 8.3%; NYHA class IV — 20.7% vs 14.4%
in favor of patients treated with beta-blockers. Due
to the fact that these clinical trials included precise-
ly selected groups of patients, it is not known wheth-
er results of these studies may be generalized, es-
pecially to patients with severe HF (NYHA class IV).
Most studies based on nationwide data and often
related to hospitalizations, lose their significance due
to low precision of the diagnostic criteria. The most
frequently referenced study is the Stewart study
from 2001 [15]. Five-year survival rate in this group
of patients was worse than it was in patients with
neoplastic disease. Probability of the survival in pa-
tients with HF was 60% in a one-year period, 45%
in a two-year period, 38% in a three-year period, and
approximately 25% in a five-year period. In epide-
miological studies related to patients with NYHA
class IV, conducted in the 1980s (standard treatment
with digitalis and diuretics), one-year mortality rate
was 50–77%; in NYHA class III it was 10–45%, and
in class II 3–25%. In all these studies, the mortality
rate in patients with NYHA class III was always sig-
nificantly higher than in NYHA class II [16].
The POLKARD-HF registry was a specific
form of data collection. It included patients with
Table 5. Multifactor Cox regression model built with the stepwise variable selection method of factors
influencing survival without emergency heart transplantation.
Parameter Hazard ratio Lower Upper P
NYHA IV 2.578 1.703 3.901 < 0.0001
NT-proBNP ≥ 4,302 pg/mL 1.600 1.074 2.385 0.0200
HFSS £ 7.19 2.572 1.721 3.845 < 0.0001
Abbreviations as in Table 1.
Table 4. Univariate Cox regression analysis of factors influencing survival without emergency heart
transplantation.
Parameter Hazard ratio estimates (univariate) P
95% confidence limits
Point estimate Lower Upper
PASP ≥ 50 mm Hg 1.270 0.876 1.840 0.2067
PCWP ≥ 25 mm Hg 1.727 1.199 2.487 0.0033
LVEF £ 17% 1.588 1.142 2.208 0.0059
NYHA IV 3.489 2.517 4.836 < 0.00001
SBP £ 90 mm Hg 1.839 1.351 2.502 0.0001
hs-CRP ≥ 6.5 mg/L 1.807 1.300 2.512 0.0004
NT-proBNP ≥ 4302 pg/mL 2.382 1.744 3.252 < 0.0001
Na £ 135 mEq/L 2.105 1.550 2.858 < 0.0001
BMI £ 23.8 kg/m2 1.270 0.916 1.762 0.1518
HFSS £ 7.19 3.248 2.378 4.435 < 0.0001
Abbreviations as in Table 1.
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severe HF below 65 years of age, initially qualified
for OHT [7]. One year prognosis in NYHA class IV
did not significantly differ from the prognosis pre-
sented in the studies conducted in the 1980s.
However, it should be emphasized that the
three-year prognosis was significantly better and it
was approximately 48%. It is possible that the com-
posite endpoint influenced results obtained within
the first year of observation. Emergency OHT mainly
applied to patients with NYHA class IV. In the cases
of all patients included into the registry, the proba-
bility of one-year survival was approximately 82%
(in the study of Stewart — 60%), two-year survival
— 75% (according to Stewart — 45%), and three-
-year survival — 68% (38%). It should be pointed out
that the patients enrolled into the study of Stewart
included patients with any functional class of HF who
were hospitalized for the first time with this diagno-
sis. Therefore, it was a population with significantly
less advanced HF [15]. Patients with NYHA classes
III and IV constituted 80% of all patients included
into the POLKARD-HF registry. The improvement
in the treatment of HF, which took place in recent
years, probably influenced the prognosis of study
subjects. Our results are in line with those of Cle-
land et al. [6] from 2001. Despite such significant
progress, the management in patients with NYHA
class IV still includes OHT as the first-line treatment.
Not only NYHA class, but also etiology of the
disease, may be important in influencing the prog-
nosis in patients with severe HF. Nevertheless, the
results of previous population and drug studies pro-
vide discrepant conclusions. Franciosa et al. [17]
recorded a significantly higher mortality rate in
patients with ischemic vs non-ischemic HF (46% vs
23%, respectively). Similar results were recorded
in the V-HeFT-I study. However, the SOLVD study
did not show any differences, emphasizing an unfa-
vorable trend among patients with ischemic cardio-
myopathy. These discrepancies may be attributed
to the varying methodologies of these studies.
In the presented results, 43% of HF was due
to the ischemic etiology, and 49% caused by dilat-
ed cardiomyopathy. No differences in the survival
rates were established. A tendency towards worse
prognosis in patients with dilated cardiomyopathy
was observed. Furthermore, significant differenc-
es in the profile of these groups were noted. The
patients with HF resulting from dilated cardiomyo-
pathy had more advanced signs of heart damage.
In these patients, significantly higher values of
NT-proBNP were recorded [18–20].
Functional classification of HF in accordance
with the New York Heart Association has led to many
controversies. In the POLKARD-HF Registry, we
conducted a detailed investigation of NYHA classes
II, III and IV. Despite all the controversies with re-
gard to NYHA classification, our results are in ac-
cordance with previous works confirming that
NYHA class IV, apart from hemodynamic, functional
and neurohumoral factors, can additionally help to
define the highest risk group among severe HF
patients [21].
Limitations of the study
The results of the registry are not representa-
tive for the whole group of patients with severe HF.
It only included patients between 18 and 65 years
of age. Our choice of the composite endpoint: death
or emergency OHT, may decrease short-term sur-
vival rate in patients, especially with NYHA class
IV. Biochemical evaluation of NT-proBNP and
hsCRP were conducted in approximately 70% of pa-
tients enrolled into the registry. The nature of the
work (registry) did not consider standardization of
obtained measurements and evaluations except for
the determination of NT-proBNP and hsCRP.
Conclusions
The prognosis in patients with severe HF has
been significantly improved over the last 20 years.
Despite an improved survival rate, the prognosis
in patients with functional NYHA class IV is still
unfavorable. Low serum sodium levels and a sub-
stantial increase in NT-proBNP negatively influ-
ence survival. OHT still remains the first-line treat-
ment in this group of patients. In our material, we
did not confirm HF etiology as a modifying factor
in patients qualified for OHT.
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